HAIFA, Israel, July 24, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial ...
Haifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial ...
Minovia Therapeutics Ltd. announced positive interim results from its Phase 2 trial of MNV-201 for Pearson Syndrome, a severe pediatric mitochondrial disease, at the United Mitochondrial Disease ...
Minovia Therapeutics said Monday that the Food and Drug Administration granted fast-track and rare-pediatric-disease designations to its lead investigational compound. The drug, MNV-201, is in Phase 2 ...
The labs found different ways to encourage stem cells to grow into a structure that resembles a human embryo, for research purposes - Copyright AFP/File AHMAD ...
Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth Data ...
Pearson Syndrome is a devastating condition seen in young children. The clinical experience from our first-generation product helped identify a novel primary endpoint for this heterogenic group of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results